Beam Therapeutics Inc. is a biotechnology company that develops precision genetic medicines using base editing technology to make single letter changes in DNA without causing double-strand breaks. The company focuses on creating treatments for serious diseases by correcting disease-causing mutations at the genetic level, with a pipeline targeting conditions including sickle cell disease, beta-thalassemia, and various cancers. Beam's base editing platform allows for more precise genetic modifications compared to traditional gene editing approaches, potentially reducing unwanted side effects while maintaining therapeutic efficacy.